January 2015
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
Delegates at this conference discussed priorities for NICE in the health and social care system, and key issues for the pharmaceutical industry.
With the Government reviewing the function, form and governance of NICE as a non-departmental public body, attendees considered how drugs should be developed, evaluated and taken up in the NHS, as well as the future for the Cancer Drugs Fund following additional £160m funding for cancer treatments not approved by NICE.
Sessions focused on the development of new standards and pathways across health, public health and social care, safe staffing levels, and next steps for medicines optimisation ahead of the expected publication of NICE guidance.
